Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: I13V • M36I • P39PS • R41K • I64V

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: None
RT Other Mutations: V35T • T39K • K43E • V60I • K102KR • D121H • K122E • I142V • K166R • D177E • I178M • Q207E • R211K • V245E • D250E

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: None
IN Other Mutations: S17N • S39C • M50MI • I72V • L101I • T112V • I113V • T124N • T125A • V201I • L234I • D256E • I267V

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

IN comments

Other

- **M50I** is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-naïve persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It may contribute to reduced DTG and CAB susceptibility in combination with R263K.

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.